PTGX 241220 2.50P (PTGX241220P2500) Stock Options, News & Quotes

Account Info

Log Out

US OptionsDetailed Quotes

PTGX241220P2500

Watchlist

0.00
0.000.00%

15min DelayClose Dec 11 09:30 ET

0.00High0.00Low

Intraday

5D
Daily

No Data

News

BTIG Upgrades Protagonist Therapeutics(PTGX.US) to Buy Rating, Maintains Target Price $67
Moomoo NewsDec 10 13:32 ET · Ratings
JMP Securities Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $58
Moomoo NewsDec 10 12:32 ET · Ratings
Optimistic Buy Rating for Protagonist Therapeutics Driven by Promising Rusfertide Data and Strategic Takeda Partnership
TipRanksDec 10 12:05 ET · Ratings
H.C. Wainwright Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $50
Moomoo NewsDec 10 07:31 ET · Ratings
Wedbush Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $58
Moomoo NewsDec 10 07:31 ET · Ratings
J.P. Morgan Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating
Moomoo NewsDec 10 07:31 ET · Ratings

Comments

71179109

Nov 20 07:50

Seems here is quiet.

$Protagonist Therapeutics (PTGX.US)$

Moomoo AI

Dec 28, 2023 06:29

Despite a growing cash burn rate, other factors hint at the company's promising trajectory. With a sensible cash runway and a low cash burn to market cap ratio, securing more funds for expansion shouldn't be an issue.

Companies Like Protagonist Therapeutics (NASDAQ:PTGX) Are In A Position To Invest In Growth

qkeep

Jul 13, 2023 05:30

$Protagonist Therapeutics (PTGX.US)$ what the hell is going on?

Distinguish07

Jul 12, 2023 09:41

Hold for long term I guess 🙌

$Protagonist Therapeutics (PTGX.US)$

Distinguish07

Jul 12, 2023 09:35

$Protagonist Therapeutics (PTGX.US)$ What’s with the crash?